The prevalence of vancomycin-intermediate Staphylococcus aureus and heterogeneous VISA among methicillin-resistant strains isolated from pediatric population in a Turkish University Hospital

Microbial Drug Resistance

Volumn 21, Issue 5, 2015, Pages 537-544

  Mirza, Hasan Cenk ^a   Sancak, Banu ^b   Gür, Deniz ^b  

^a Merzifon Public Hospital Amasya   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; METICILLIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EPSILOMETER TEST; HETEROGENOUS VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEDIATRIC HOSPITAL; POPULATION ANALYSIS PROFILE AREA UNDER THE CURVE METHOD; PREVALENCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TURKEY (REPUBLIC); TURKISH CITIZEN; UNIVERSITY HOSPITAL; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; AREA UNDER THE CURVE; CHILD; DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; STAPHYLOCOCCAL INFECTIONS; TURKEY;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TURKEY; VANCOMYCIN;

EID: 84943258221     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2015.0048     Document Type: Article

References (54)

1. Adam, H.J., L. Louie, C. Watt, D. Gravel, E. Bryce, M. Loeb, A. Matlow, A. McGreer, M.R. Mulvey, A.E. Simor; Canadian Nosocomial Infection Surveillance Program. 2010. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob. Agents Chemother. 54:945-949.
2. Alos, J.I., A. Garcia-Canas, P. Garcia-Hierro, and F. Rodriguez-Salvanes. 2008. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J. Antimicrob. Chemother. 62:773-775.
3. Appelbaum, P.C. 2007. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30:398-408.
4. Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, J. Linares, J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588.
5. Bae, I.G., J.J. Federspiel, J.M. Miró, C.W. Woods, L. Park, M.J. Rybak, et al. 2009. Heterogeneous vancomycinintermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J. Infect. Dis. 200:1355-1366.
6. Charles, P.G., P.B. Ward, P.D. Johnson, B.P. Howden, and M.L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451.
7. Chen, H., Y. Liu, W. Sun, M. Chen, and H. Wang. 2011. The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC. Diagn. Microbiol. Infect. Dis. 71:301-303.
8. Clinical and Laboratory Standards Institute. 2009. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Eighth Edition. Approved Standard M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute. 2011. Performance Standards for Antimicrobial Susceptibility Testing. Twenty-First Informational Supplement. M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Fong, R.K., J. Low, T.H. Koh, and A. Kurup. 2009. Clinical features and treatment outcomes of vancomycinintermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur. J. Clin. Microbiol. Infect. Dis. 28:983-987.
11. Goldman, J.L., C.J. Harrison, A.L. Myers, M.A. Jackson, and R. Selvarangan. 2014.No evidence of vancomycin minimal inhibitory concentration creep or heteroresistance identified in pediatric Staphylococcus aureus blood isolates. Pediatr. Infect. Dis. J. 33:216-218.
12. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
13. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F.C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
14. Ho, P.L., P.Y. Lo, K.H. Chow, E.H. Lau, E.L. Lai, V.C. Cheng, and R.Y. Kao. 2010. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J. Infect. 60:140-145.
15. Holmes, R.L., and J.H. Jorgensen. 2008. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob. Agents Chemother. 52: 757-760.
16. Horne, K.C., B.P. Howden, E.A. Grabsch, M. Graham, P.B. Ward, S. Xie, B.C. Mayall, P.D. Johnson, and M.L. Grayson. 2009. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycinsusceptible MRSA. Antimicrob. Agents Chemother. 53: 3447-3452.
17. Howden, B.P., J.K. Davies, P.D. Johnson, T.P. Stinear, and M.L. Grayson. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycinintermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
18. Howden, B.P., P.B. Ward, P.G. Charles, T.M. Korman, A. Fuller, P. du Cros, E.A. Grabsch, S.A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P.D. Johnson, A.J. Morris, B.C. Mayall, and M.L. Grayson. 2004. Treatment outcomes for serious infections caused by methicillinresistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.
19. Hsu, D.I., L.K. Hidayat, R. Quist, J. Hindler, A. Karlsson, A. Yusof, and A. Wong-Beringer. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32: 378-385.
20. Jimenez-Truque, N., I. Thomsen, E. Saye, and C.B. Creech. 2010. Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children? Pediatr. Infect. Dis. J. 29:368-370.
21. Kao, T.M., J.T. Wang, C.M. Weng, Y.C. Chen, and S.C. Chang. 2011. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC. J. Microbiol. Immunol. Infect. 44:346-351.
22. Keel, R.A., C.A. Sutherland, J. Aslanzadeh, D.P. Nicolau, and J.L. Kuti. 2010. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn. Microbiol. Infect. Dis. 68:326-329.
23. Kehrmann, J., M. Kaase, F. Szabados, S.G. Gatermann, J. Buer, P.M. Rath, and J. Steinmann. 2011. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur. J. Clin. Microbiol. Infect. Dis. 30:677-683.
24. Kosowska-Shick, K., L.M. Ednie, P. McGhee, K. Smith, C.D. Todd, A. Wehler, and P.C. Appelbaum. 2008. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center. Antimicrob. Agents Chemother. 52:4510-4513.
25. Kusxcu, F., D.B. Oztürk, Y. Gürbüz, E.E. Tütüncü, I. Sencan, and S. Gül. 2011. Investigation of reduced vancomycin susceptibility in methicillin-resistant staphylococci. Mikrobiyol. Bul. 45:248-257.
26. Lodise, T.P., J. Graves, A. Evans, E. Graffunder, M. Helmecke, B.M. Lomaestro, and K. Stellrecht. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
27. Machado, D.P., F. Nagel, V.R. Aquino, D. de Souza Martins, R. Nazario, L.Z. Goldani, and R.P. dos Santos. 2010. Vancomycin minimal inhibitory concentration from broth microdilution and Etest in respiratory tract samples of patients with ventilation-associated pneumonia. J. Hosp. Infect. 76:182-184.
28. Maor, Y., M. Hagin, N. Belausov, N. Keller, D. Ben-David, and G. Rahav. 2009. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
29. Maor, Y., G. Rahav, N. Belausov, D. Ben-David, G. Smollan, and N. Keller. 2007. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J. Clin. Microbiol. 45:1511-1514.
30. Moise, P.A., and J.J. Schentag. 2000. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int. J. Antimicrob. Agents 16(Suppl 1): 31-34.
31. Munoz-Cobo, B., S. Sancho-Tello, E. Costa, D. Bravo, I. Torregrosa, J.G. de Lomas, and D. Navarro. 2011. Differences in vancomycin minimum inhibitory concentrations for Staphylococcus aureus obtained with the automated Phoenix system, the Clinical and Laboratory Standards Institute broth microdilution method and the standard Etest. Int. J. Antimicrob. Agents 37:278-279.
32. Musta, A.C., K. Riederer, S. Shemes, P. Chase, J. Jose, L.B. Johnson, and R. Khatib. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640-1644.
33. Prakash, V., J.S. Lewis 2nd, and J.H. Jorgensen. 2008. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother. 52:4528.
34. Reynolds, R., R. Hope, M. Warner, A.P. MacGowan, D.M. Livermore, M.J. Ellington; BSAC Extended Working Party on Resistance Surveillance. 2012. Lack of upward creep of glycopeptide MICs for methicillinresistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-2007. J. Antimicrob. Chemother. 67:2912-2918.
35. Richter, S.S., S.W. Satola, E.K. Crispell, K.P. Heilmann, C.L. Dohrn, F. Riahi, A.J. Costello, D.J. Diekema, and G.V. Doern. 2011. Detection of Staphylococcus aureus with heterogeneous intermediate-level resistance to vancomycin in the United States. J. Clin. Microbiol. 49:4203-4207.
36. Riederer, K., S. Shemes, P. Chase, A.Musta, A.Mar, and R. Khatib. 2011. Detection of intermediately vancomycinsusceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and agar screening methods. J. Clin. Microbiol. 49:2147-2150.
37. Rybak, M.J., S.N. Leonard, K.L. Rossi, C.M. Cheung, H.S. Sader, and R.N. Jones. 2008. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46:2950-2954.
38. Sader, H.S., G.J. Moet, D.J. Farrell, and R.N. Jones. 2011. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Diagn. Microbiol. Infect. Dis. 70:412-416.
39. Sader, H.S., P.R. Rhomberg, and R.N. Jones. 2009. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:3162-3165.
40. Sader, H.S., A.A. Watters, T.R. Fritsche, and R.N. Jones. 2007. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycinresistant enterococci isolated in European medical centers (2005). BMC Infect. Dis. 7:29.
41. Sakoulas, G., P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering, Jr., and G.M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
42. Sancak, B., S. Ercis, D. Menemenlioglu, S. Colakoglu, and G. Hasçelik. 2005. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J. Antimicrob. Chemother. 56:519-523.
43. Sancak, B., S. Yagci, D. Gür, Z. Gülay, D. Ogunc, G. Söyletir, A.N. Yalcin, D.O. Dündar, A.W. Topçu, F. Aksit, G. Usluer, C. Ozakin, H. Akalin, M. Hayran, and V. Korten. 2013. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey. BMC Infect. Dis. 13:583.
44. Sancak, B., S. Yagci, H.C. Mirza, and G. Hasçelik. 2013. Evaluation of vancomycin and daptomycin MIC trends for methicillin-resistant Staphylococcus aureus blood isolates over an 11 year period. J. Antimicrob. Chemother. 68: 2689-2691.
45. Satola, S.W., M.M. Farley, K.F. Anderson, and J.B. Patel. 2011. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J. Clin. Microbiol. 49:177-183.
46. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-2005. J. Antimicrob. Chemother. 60:788-794.
47. Sujatha, S., and I. Praharaj. 2012. Glycopeptide resistance in gram-positive cocci: a review. Interdiscip. Perspect. Infect. Dis. 2012:781679.
48. van Hal, S.J., T. Barbagiannakos, M. Jones, M.C. Wehrhahn, J. Mercer, D. Chen, D.L. Paterson, and I.B. Gosbell. 2011. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J. Antimicrob. Chemother. 66:2284-2287.
49. van Hal, S.J., M.C. Wehrhahn, T. Barbagiannakos, J. Mercer, D. Chen, D.L. Paterson, and I.B. Gosbell. 2011. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J. Clin. Microbiol. 49: 1489-1494.
50. Walsh, T.R., A. Bolmström, A. Qwarnström, P. Ho, M. Wootton, R.A. Howe, A.P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.
51. Welsh, K.J., A.N. Abbott, E.M. Lewis, J.M. Gardiner, M.C. Kruzel, C.T. Lewis, J.F. Mohr, A. Wanger, and L.Y. Armitige. 2010. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J. Clin. Microbiol. 48:894-899.
52. Wootton, M., R.A. Howe, R. Hillman, T.R. Walsh, P.M. Bennett, and A.P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect heteroresistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.
53. Wootton, M., A.P. MacGowan, T.R. Walsh, and R.A. Howe. 2007. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 45:329-332.
54. Yeh, Y.C., K.M. Yeh, T.Y. Lin, S.K. Chiu, Y.S. Yang, Y.C. Wang, and J.C. Lin. 2012. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia. J. Microbiol. Immunol. Infect. 45:214-220.